PubMed · 1997 · 14 citations · 0 references
MedicinePharmacologyPsychiatryClinical PharmacologyNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyDepression PharmacotherapySerotonergic PharmacologySerotonergic SignalingAntidepressant MedicationsPharmacology Of Serotonergic AgentsSelective Serotonin Reuptake Inhibitor InteractionsSelective Serotonin Reuptake Inhibitor TreatmentSelective Serotonin Reuptake Inhibitor UseSerotonin Receptor PharmacologySerotonin Syndrome ManagementSerotonin Toxicity
We present the case of a 35-year-old woman who developed serotonin syndrome after receiving a single dose of the cyclic antidepressant imipramine (Tofranil). She was already being treated for depression with paroxetine (Paxil), a selective serotonin reuptake inhibitor. Two hours after receiving imipramine, the patient developed tachycardia, delirium, bizarre movements, and myoclonus, all classic findings of serotonin syndrome. Her antidepressants were discontinued and she was treated with intravenous fluids, sedation, and a short course of cyproheptadine, a serotonin receptor antagonist. All symptoms resolved completely within 24 hours. In this case report, we review the drug interactions that can precipitate serotonin syndrome, and give recommendations for the diagnosis and treatment of this potentially fatal disorder.